Carlsmed closed a $10 million Series A financing to commercialize a digital + surgical planning solution and personalized aprevo™ implants for the correction of spinal deformity.
This joins an oversubscribed $2.5 million seed round which closed earlier this year.
Carlsmed was granted FDA 510(k) clearance and Breakthrough Device Designation by FDA for aprevo patient-specific interbody devices for the correction of adult spinal deformity. The aprevo device is reportedly the first implant to receive both Breakthrough Device Designation and 510(k) market clearance from FDA.
“This round of financing comes at the perfect time to meet surgeon and patient demand for the newly launched Breakthrough aprevo devices. U.S. Venture Partners is the right fit for our digital + surgical company, being the leading Silicon Valley VC focused on early stage IT and healthcare. Their track record of building and scaling transformative companies is second to none.” - Mike Cordonnier, CEO of Carlsmed